Evonik’s Strategic Pivot: A Moratorium on Acquisitions to Fortify Finances

In a decisive shift of corporate strategy, German specialty chemicals group Evonik has placed a firm hold on any acquisition activity until at least 2027. This is not a tentative guideline but a clear operational priority: debt reduction now unequivocally takes precedence over external growth. Company leadership has recently reiterated this position to analysts, leaving no room for ambiguity regarding its near-term capital allocation focus.

A Sharper Focus Through Divestments

Central to this strategic realignment is the systematic divestiture of non-core, cyclical business units. Two entities are prominently on the block: Syneqt, the operator of chemical parks in Marl and Wesseling, and the Oxeno division. Syneqt was already carved out as an independent entity at the beginning of 2026, and its sale process remains ongoing. Through these disposals, Evonik aims to make targeted reductions in its net debt while refining its corporate identity as a pure-play specialty chemicals company.

Running parallel to the asset sales is a comprehensive efficiency program targeting annual savings of €400 million by the end of 2026. This initiative is expected to result in the elimination of up to 2,000 positions globally.

Operational Bright Spot: Strength in Animal Nutrition

On the operational front, Evonik’s animal nutrition business is providing a welcome boost. The company has implemented a global 10% price increase for its MetAMINO feed additive. This move is supported by supply constraints in Asia, where a force majeure declaration at a methionine production site in Singapore has further tightened global supply.

Should investors sell immediately? Or is it worth buying Evonik?

For the full 2026 fiscal year, management has reaffirmed its guidance, projecting adjusted EBITDA to land between €1.7 billion and €2.0 billion. This compares to a result of €1.87 billion achieved in the prior year, 2025.

Dividend Policy Shifts to a Variable Model

Commencing with the current fiscal year, Evonik is overhauling its shareholder remuneration framework. The company is abandoning a fixed dividend payout—which stood at €1.00 per share for 2025—in favor of a variable policy. Going forward, distributions will be set at 40% to 60% of the group’s adjusted net income. This new formula grants management greater flexibility to accelerate debt repayment but introduces more uncertainty for investors regarding the precise future payout level.

Evonik’s share price currently trades around €14.13, slightly below its 200-day moving average. Since March 2025, the stock has shed approximately one-third of its value. The critical question for investors is whether the confirmed annual outlook, combined with the rigorous portfolio restructuring, will be sufficient to narrow the valuation gap with its specialty chemicals peers. A definitive answer may only emerge once the sales processes for Syneqt and Oxeno reach their conclusion.